Most patients with migraine who underwent a greater occipital nerve block for treatment reported moderate to significant positive responses, according to findings recently published in the Journal of ...

The new document raises IV prochlorperazine and greater occipital nerve blocks to must-offer status and states that opioids ...

Lidocaine injections into the greater occipital nerve relieve severe, refractory migraine attacks in children, results of a randomized controlled trial show. Investigators found children receiving ...

Guideline states that prochlorperazine IV and greater occipital nerve blocks must be offered to eligible adults requiring parenteral therapy. HealthDay News — The American Headache Society has updated ...

According to a study published in Headache, greater occipital nerve blocks (GONB) with bupivacaine were not as effective as intravenous (IV) metoclopramide as a first-line treatment for migraineurs ...

Please provide your email address to receive an email when new articles are posted on . The study included 58 young persons with migraine flares lasting 24 hours to 3 months. A majority of those given ...

A new study by Phoenix's Barrow Neurological Institute and the University of Calgary has found which injectable treatments showed the most benefit for migraine patients and should be routinely offered ...

People hospitalized for a debilitating migraine should receive targeted nerve blocks rather than IV opioids, new treatment guidelines suggest. Photo by Adobe Stock/HealthDay News People hospitalized ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Neurologist Dr.

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors ...

The American Headache Society updates guidelines on the use of parenteral pharmacologic therapies for migraine attack management in the ED.